Pharmaceutical companies are racing to snap up innovative biotechs with a flurry of bolt-on purchases, shying away from the megadeals that once marked the sector as they attempt to fill looming gaps in their pipelines.
To read the entire story, you must be logged in.
Please log in now or register with us.
